Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 5 de 5
Filter
Add more filters










Database
Language
Publication year range
1.
Am J Pathol ; 193(1): 27-38, 2023 01.
Article in English | MEDLINE | ID: mdl-36309105

ABSTRACT

Inadequate DNA damage response related to ataxia telangiectasia mutated gene restricts hepatic regeneration in acute liver failure. Resolving mechanistic gaps in liver damage and repair requires additional animal models that are unconstrained by ultrarapid and unpredictable mortalities or substantial divergences from human pathology. This study used Fischer 344 rats primed with the antitubercular drug, rifampicin, plus phenobarbitone, and monocrotaline, a DNA adduct-forming alkaloid. Rifampicin and monocrotaline can cause liver failure in people. This regimen resulted in hepatic oxidative stress, necrosis, DNA double-strand breaks, liver test abnormalities, altered serum cytokine expression, and mortality. Healthy donor hepatocytes were transplanted ectopically in the peritoneal cavity to study whether they could supply metabolic support and rebalance inflammatory or protective cytokines affecting liver regeneration events. Hepatocyte transplantation increased candidate cytokine levels (granulocyte colony-stimulating factor, granulocyte-macrophage colony-stimulating factor, interferon-γ, IL-10, and IL-12), leading to Atm, Stat3, and Akt signaling in hepatocytes and nonparenchymal cells, lowering of inflammation, and improvements in intermediary metabolism, DNA repair, and hepatocyte proliferation. Such control of DNA damage and inflammation, along with stimulation of hepatic growth, offers paradigms for cell signaling to restore hepatic homeostasis and regeneration in acute liver failure. Further studies of molecular pathways of high pathobiological impact will advance the knowledge of liver regeneration.


Subject(s)
Ataxia Telangiectasia , Liver Failure, Acute , Rats , Humans , Animals , Ataxia Telangiectasia/metabolism , Ataxia Telangiectasia/pathology , Monocrotaline/metabolism , Rifampin/metabolism , Cytokines/metabolism , Liver Failure, Acute/metabolism , Liver/metabolism , Liver Regeneration/physiology , Hepatocytes/pathology , Rats, Inbred F344 , Inflammation/pathology
2.
FASEB J ; 35(4): e21471, 2021 04.
Article in English | MEDLINE | ID: mdl-33683737

ABSTRACT

Acute liver failure constitutes a devastating condition that needs novel cell and molecular therapies. To elicit synergisms in cell types of therapeutic interest, we studied hepatocytes and liver sinusoidal endothelial in mice with acetaminophen-induced acute liver failure. The context of regenerative signals was examined by transplants in peritoneal cavity because it possesses considerable capacity and allows soluble signals to enter the systemic circulation. Whereas transplanted hepatocytes and liver sinusoidal endothelial cells engrafted in peritoneal cavity, only the former could rescue mice in liver failure by improving injury outcomes, activating hepatic DNA damage repair, and inducing liver regeneration. The cytokines secreted by donor hepatocytes or liver sinusoidal endothelial cells differed and in hepatocytes from mice undergoing acetaminophen toxicity major cytokines were even rendered deficient (eg, G-CSF, VEGF, and others). Significantly, recapitulating hepatotoxicity-related DNA damage response in cultured cells identified impairments in ATM and JAK/STAT3 intersections since replacing cytokines produced less from injured hepatocytes restored these pathways to avoid acetaminophen hepatotoxicity. Similarly, hepatocyte transplantation in acute liver failure restored ATM and JAK/STAT3 pathways to advance DNA damage/repair and liver regeneration. The unexpected identification of novel hepatic G-CSF receptor expression following injury allowed paradigmatic studies of G-CSF supplementation to confirm the centrality of this paracrine ATM and STAT3 intersection. Remarkably, DNA damage/repair and hepatic regeneration directed by G-CSF concerned rebalancing of regulatory gene networks overseeing inflammation, metabolism, and cell viability. We conclude that healthy donor hepatocytes offer templates for generating specialized cell types to replace metabolic functions and regenerative factors in liver failure.


Subject(s)
Chemical and Drug Induced Liver Injury/drug therapy , Endothelial Cells/drug effects , Hepatocytes/cytology , Liver Failure, Acute/therapy , Liver Regeneration/drug effects , Acetaminophen/pharmacology , Animals , Cell Survival/physiology , Chemical and Drug Induced Liver Injury/metabolism , Humans , Liver Failure, Acute/chemically induced , Liver Failure, Acute/metabolism , Liver Regeneration/physiology , STAT3 Transcription Factor/metabolism
3.
Am J Pathol ; 191(1): 79-89, 2021 01.
Article in English | MEDLINE | ID: mdl-33127336

ABSTRACT

The innate immune system plays a critical role in allograft rejection. Alloresponses involve numerous cytokines, chemokines, and receptors that cause tissue injury during rejection. To dissect these inflammatory mechanisms, we developed cell transplantation models in dipeptidylpeptidase-deficient F344 rats using mycophenolate mofetil and tacrolimus for partial lymphocyte-directed immunosuppression. Syngeneic hepatocytes engrafted in liver, whereas allogeneic hepatocytes were rejected but engrafted after immunosuppression. These transplants induced mRNAs for >40 to 50 cytokines, chemokines, and receptors. In allografts, innate cell type-related regulatory networks extended to granulocytes, monocytes, and macrophages. Activation of Tnfa and its receptors or major chemokine receptor-ligand subsets persisted in the long term. An examination of the contribution of Tnfa in allograft response revealed that it was prospectively antagonized by etanercept or thalidomide, which resolved cytokine, chemokine, and receptor cascades. In bioinformatics analysis of upstream regulator networks, the Cxcl8 pathway exhibited dominance despite immunosuppression. Significantly, Tnfa antagonism silenced the Cxcl8 pathway and decreased neutrophil and Kupffer cell recruitment, resulting in multifold greater engraftment of allogeneic hepatocytes and substantially increased liver repopulation in retrorsine/partial hepatectomy model. We conclude that Tnfa is a major driver for persistent innate immune responses after allogeneic cells. Neutralizing Tnfa should help in avoiding rejection and associated tissue injury in the allograft setting.


Subject(s)
Graft Rejection/immunology , Hepatocytes/transplantation , Immunity, Innate/immunology , Transplantation Immunology/immunology , Tumor Necrosis Factor-alpha/immunology , Allografts , Animals , Rats , Rats, Inbred F344 , Rats, Long-Evans , Transplantation, Homologous
4.
Hum Gene Ther ; 30(3): 365-377, 2019 03.
Article in English | MEDLINE | ID: mdl-30266073

ABSTRACT

Reconstitution of healthy endothelial cells in vascular beds offers opportunities for mechanisms in tissue homeostasis, organ regeneration, and correction of deficient functions. Liver sinusoidal endothelial cells express unique functions, and their transplantation is relevant for disease models and for cell therapy. As molecular targets for improving transplanted cell engraftment and proliferation will be highly significant, this study determined whether ETA/B receptor antagonism by the drug bosentan could overcome cell losses due to cell transplantation-induced cytotoxicity. Cell engraftment and proliferation assays were performed with healthy wild-type liver sinusoidal endothelial cells transplanted into the liver of dipeptidylpeptidase IV knockout mice. Transplanted cells were identified in tissues by enzyme histochemistry. Cells with prospective ETA/B antagonism engrafted significantly better in hepatic sinusoids. Moreover, these cells underwent multiple rounds of division under liver repopulation conditions. The gains of ETA/B antagonism resulted from benefits in cell viability and membrane integrity. Also, in bosentan-treated cells, mitochondrial homeostasis was better maintained with less oxidative stress and DNA damage after injuries. Intracellular effects of ETA/B antagonism were transduced by conservation of ataxia telangiectasia mutated protein, which directs DNA damage response. Therefore, ETA/B antagonism in donor cells will advance vascular reconstitution. Extensive experience with ETA/B antagonists will facilitate translation in people.


Subject(s)
Endothelial Cells/drug effects , Endothelial Cells/metabolism , Endothelin Receptor Antagonists/pharmacology , Liver/blood supply , Liver/drug effects , Microvessels/drug effects , Animals , Cell Survival/drug effects , Cytoskeleton/metabolism , DNA Damage , Dipeptidyl Peptidase 4/deficiency , Liver/metabolism , Liver/pathology , Membrane Potential, Mitochondrial/drug effects , Mice , Mice, Knockout , Mitochondria, Liver/drug effects , Mitochondria, Liver/metabolism , Models, Biological , Oxidative Stress , Reactive Oxygen Species/metabolism
5.
Methods Mol Biol ; 1506: 161-178, 2017.
Article in English | MEDLINE | ID: mdl-27830552

ABSTRACT

Wilson's disease (WD) is characterized by the inability to excrete copper (Cu) from the body with progressive tissue injury, especially in liver and brain. The molecular defect in WD concerns mutations in ATP7B gene leading to loss of Cu transport from the hepatocyte to the bile canaliculus. While drugs, e.g., Cu chelators, have been available for several decades, these must be taken lifelong, which can be difficult due to issues of compliance or side effects. Many individuals may require liver transplantation, which can also be difficult due to donor organ shortages. Therefore, achieving permanent cures via cell or gene therapy are of great interest for WD. Cell therapy is feasible because transplanted hepatocytes can integrate in liver parenchyma and restore deficient functions, including transport of Cu into bile. The availability of authentic animal models that recapitulate hepatic WD, especially the Long-Evans Cinnamon (LEC) rat, has advanced cell transplantation research in WD. We describe requirements for cell therapy in animal models with several standardized methods for studies to test or refine cell therapy strategies in WD.


Subject(s)
Cell Transplantation/methods , Disease Models, Animal , Hepatocytes/transplantation , Hepatolenticular Degeneration/therapy , Rats, Inbred LEC/physiology , Animals , Cell Transplantation/adverse effects , Cell Transplantation/instrumentation , Copper/metabolism , Copper-Transporting ATPases/genetics , Genetic Therapy/methods , Hepatobiliary Elimination , Hepatolenticular Degeneration/genetics , Hepatolenticular Degeneration/pathology , Humans , Liver/cytology , Liver/pathology , Liver/surgery , Liver Transplantation/adverse effects , Mutation , Rats , Rats, Inbred LEC/surgery
SELECTION OF CITATIONS
SEARCH DETAIL
...